Dong-A St

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. Its portfolio includes ethical drugs such as Clofazimine cap. for lepromatous leprosy, Closerin Cap for tuberculosis, Eporon inj./PFS for renal anemia, Gemcit inj. for various cancers, Gonadopin inj./PFS for fertility issues, Growtropin II Inj. for growth disorders, Leucostim Inj. for neutropenia, Mainta inj. for lung cancer and mesothelioma, Monotaxel inj. for multiple cancers, Motilitone tab. for functional dyspepsia, Stillen tab. for gastritis, Suganon tab. and related products for type 2 diabetes, DA-3880 PFS for renal anemia, and Zydena tab. for erectile dysfunction. The company also provides licensed-in and licensed-out drugs, as well as medical devices including high-technology devices, custom-made products, and artificial cardiac circuits for open-heart surgery. Founded in 1932, Dong-A ST is headquartered in Seoul, South Korea.